Cargando…

Pilot study of a novel serum mRNA gene panel for diagnosis of acute septic arthritis

BACKGROUND: Septic arthritis is an orthopedic emergency requiring immediate surgical intervention. Current diagnostic standard of care is an invasive joint aspiration. Aspirations provide information about the inflammatory cells in the sample within a few hours, but there is often ambiguity about wh...

Descripción completa

Detalles Bibliográficos
Autores principales: Schultz, Blake J, Sweeney, Timothy, DeBaun, Malcolm R, Remmel, Melissa, Midic, Uros, Khatri, Purvesh, Gardner, Michael J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6937427/
https://www.ncbi.nlm.nih.gov/pubmed/31908991
http://dx.doi.org/10.5312/wjo.v10.i12.424
_version_ 1783483874142060544
author Schultz, Blake J
Sweeney, Timothy
DeBaun, Malcolm R
Remmel, Melissa
Midic, Uros
Khatri, Purvesh
Gardner, Michael J
author_facet Schultz, Blake J
Sweeney, Timothy
DeBaun, Malcolm R
Remmel, Melissa
Midic, Uros
Khatri, Purvesh
Gardner, Michael J
author_sort Schultz, Blake J
collection PubMed
description BACKGROUND: Septic arthritis is an orthopedic emergency requiring immediate surgical intervention. Current diagnostic standard of care is an invasive joint aspiration. Aspirations provide information about the inflammatory cells in the sample within a few hours, but there is often ambiguity about whether the source is infectious (e.g. bacterial) or non-infectious (e.g. gout). Cultures can take days to result, so decisions about surgery are often made with incomplete data. Novel diagnostics are thus needed. The “Sepsis MetaScore” (SMS) is an 11-mRNA host immune blood signature that can distinguish between infectious and non-infectious acute inflammation. It has been validated in multiple cohorts across heterogeneous clinical settings. AIM: To study whether the SMS holds diagnostic validity in determining the etiology of acute arthritis. METHODS: We conducted a blinded, prospective, non-interventional clinical study of the SMS. All patients undergoing work-up for a septic primary joint were enrolled. Patients proceeded through the normal standard-of-care pathway, including joint aspiration and inflammatory labs [white blood cell (WBC), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP)]. Venous blood was also drawn into PAX gene RNA-stabilizing tubes and mRNAs were measured using Nano String nCounter™. SMS was calculated blinded to clinical results. RESULTS: A total of 20 samples were included, of which 11 were infected based on aspiration or intra-operative cultures. The SMS had an area under the ROC curve (AUROC) of 0.87 for separating infectious from non-infectious conditions. For comparison, the AUROCs for ESR = 0.58, CRP = 0.6, and WBC = 0.59. At 100% sensitivity for infection, the specificity of the SMS was 40%, meaning nearly half of non-septic patients could have been ruled out for further intervention. CONCLUSION: In this pilot study, SMS showed a high level of diagnostic accuracy in predicting septic joints compared to other diagnostic biomarkers. This quick blood test could be an important tool for early, accurate identification of acute septic joints and need for emergent surgery, improving clinical care and healthcare spending.
format Online
Article
Text
id pubmed-6937427
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-69374272020-01-06 Pilot study of a novel serum mRNA gene panel for diagnosis of acute septic arthritis Schultz, Blake J Sweeney, Timothy DeBaun, Malcolm R Remmel, Melissa Midic, Uros Khatri, Purvesh Gardner, Michael J World J Orthop Basic Study BACKGROUND: Septic arthritis is an orthopedic emergency requiring immediate surgical intervention. Current diagnostic standard of care is an invasive joint aspiration. Aspirations provide information about the inflammatory cells in the sample within a few hours, but there is often ambiguity about whether the source is infectious (e.g. bacterial) or non-infectious (e.g. gout). Cultures can take days to result, so decisions about surgery are often made with incomplete data. Novel diagnostics are thus needed. The “Sepsis MetaScore” (SMS) is an 11-mRNA host immune blood signature that can distinguish between infectious and non-infectious acute inflammation. It has been validated in multiple cohorts across heterogeneous clinical settings. AIM: To study whether the SMS holds diagnostic validity in determining the etiology of acute arthritis. METHODS: We conducted a blinded, prospective, non-interventional clinical study of the SMS. All patients undergoing work-up for a septic primary joint were enrolled. Patients proceeded through the normal standard-of-care pathway, including joint aspiration and inflammatory labs [white blood cell (WBC), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP)]. Venous blood was also drawn into PAX gene RNA-stabilizing tubes and mRNAs were measured using Nano String nCounter™. SMS was calculated blinded to clinical results. RESULTS: A total of 20 samples were included, of which 11 were infected based on aspiration or intra-operative cultures. The SMS had an area under the ROC curve (AUROC) of 0.87 for separating infectious from non-infectious conditions. For comparison, the AUROCs for ESR = 0.58, CRP = 0.6, and WBC = 0.59. At 100% sensitivity for infection, the specificity of the SMS was 40%, meaning nearly half of non-septic patients could have been ruled out for further intervention. CONCLUSION: In this pilot study, SMS showed a high level of diagnostic accuracy in predicting septic joints compared to other diagnostic biomarkers. This quick blood test could be an important tool for early, accurate identification of acute septic joints and need for emergent surgery, improving clinical care and healthcare spending. Baishideng Publishing Group Inc 2019-12-18 /pmc/articles/PMC6937427/ /pubmed/31908991 http://dx.doi.org/10.5312/wjo.v10.i12.424 Text en ©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Basic Study
Schultz, Blake J
Sweeney, Timothy
DeBaun, Malcolm R
Remmel, Melissa
Midic, Uros
Khatri, Purvesh
Gardner, Michael J
Pilot study of a novel serum mRNA gene panel for diagnosis of acute septic arthritis
title Pilot study of a novel serum mRNA gene panel for diagnosis of acute septic arthritis
title_full Pilot study of a novel serum mRNA gene panel for diagnosis of acute septic arthritis
title_fullStr Pilot study of a novel serum mRNA gene panel for diagnosis of acute septic arthritis
title_full_unstemmed Pilot study of a novel serum mRNA gene panel for diagnosis of acute septic arthritis
title_short Pilot study of a novel serum mRNA gene panel for diagnosis of acute septic arthritis
title_sort pilot study of a novel serum mrna gene panel for diagnosis of acute septic arthritis
topic Basic Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6937427/
https://www.ncbi.nlm.nih.gov/pubmed/31908991
http://dx.doi.org/10.5312/wjo.v10.i12.424
work_keys_str_mv AT schultzblakej pilotstudyofanovelserummrnagenepanelfordiagnosisofacutesepticarthritis
AT sweeneytimothy pilotstudyofanovelserummrnagenepanelfordiagnosisofacutesepticarthritis
AT debaunmalcolmr pilotstudyofanovelserummrnagenepanelfordiagnosisofacutesepticarthritis
AT remmelmelissa pilotstudyofanovelserummrnagenepanelfordiagnosisofacutesepticarthritis
AT midicuros pilotstudyofanovelserummrnagenepanelfordiagnosisofacutesepticarthritis
AT khatripurvesh pilotstudyofanovelserummrnagenepanelfordiagnosisofacutesepticarthritis
AT gardnermichaelj pilotstudyofanovelserummrnagenepanelfordiagnosisofacutesepticarthritis